1. Anonymous (2009) Senators Announce Bipartisan Proposal To Bring Generic Biologic Drugs To Market, Saving Billions In Medicare Costs [Press release, 26 March 2009] (http://vitter.senate.gov/public/index.cfm?FuseAction=PressRoom.PressReleases&ContentRecord_id=482f3d72-a00d-ec7a-e599-a874f852c445&Region_id=&Issue_id=1440e2b6-2a4f-433e-b31a-58a675aa6790, accessed April 2, 2009)
2. Editorial (2008) Merck to Develop Biotech Generics, The Wall Street Journal 10 December, p. B1 (http://online.wsj.com/article/SB122883224274591361.html?mod=wsjcrmain, accessed April 2, 2009)
3. Pure red-cell aplasia and epoetin therapy;Bennett;N. Engl. J. Med.,2004
4. Woodcock, J. (2007) Follow-on Protein Products: Statement of Janet Woodcock, M.D. Deputy Commissioner, Chief Medical Officer, Food and Drug Administration, before The Committee on Oversight and Government Reform United States House of Representatives, March 26, 2007 (http://www.fda.gov/NewsEvents/Testimony/ucm154070.htm, accessed June 15, 2009)
5. Pierson, R. (2009) Genzyme's Lumizyme faces delay after FDA rejection, Reuters 2 March (http://www.reuters.com/article/healthNews/idUSTRE5216V020090302, accessed April 3, 2009)